US2011274688A1PendingUtilityA1

Prevention of tumors with monoclonal antibodies against neu

62
Assignee: UNIV PENNSYLVANIAPriority: Mar 30, 1993Filed: Jul 19, 2011Published: Nov 10, 2011
Est. expiryMar 30, 2013(expired)· nominal 20-yr term from priority
Inventors:Mark I. GreeneMakoto KatsumataJeffrey Drebin
A61K 38/00C07K 16/32A61P 35/00A61K 2039/505
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed.

Claims

exact text as granted — not AI-modified
1 . A method of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces, said method comprising the steps of:
 a) identifying said individual; and,   b) administering to said individual an antibody which specifically binds to p185.   
     
     
         2 . The method of  claim 1  wherein the antibody has the complementarity determining regions from an antibody selected from the group consisting of 7.16.4 and 7.9.5. 
     
     
         3 . The method of  claim 1  wherein the antibody has the variable region from an antibody selected from the group consisting of 7.16.4 and 7.9.5. 
     
     
         4 . The method of  claim 1  wherein the antibody is selected from the group consisting of 7.16.4 and 7.9.5. 
     
     
         5 . The method of  claim 1  wherein the antibody is 7.16.4. 
     
     
         6 . The method of  claim 1  wherein the antibody is a humanized antibody with complementarity determining regions selected from an antibody the group consisting of 7.16.4 and 7.9.5. 
     
     
         7 . The method of  claim 1  wherein the antibody is a humanized antibody with complementarity determining regions from antibody 7.16.4. 
     
     
         8 . The method of  claim 1  wherein the antibody is a humanized antibody with variable regions selected from an antibody the group consisting of 7.16.4 and 7.9.5. 
     
     
         9 . The method of  claim 1  wherein the antibody is a humanised antibody with variable regions from antibody 7.16.4. 
     
     
         10 . The method of  claim 1  further comprising administering to said individual a second antibody which specifically binds to p185. 
     
     
         11 . The method of  claim 1  further comprising administering to said individual an anti-tumor agent. 
     
     
         12 . A method of preventing transformation of a normal cell into a tumor cell that has p185 on its surface in individual who has had a tumor that has p185 on its cell surfaces removed or who has had cancer characterised by tumor cells that have p185 on their surfaces enter remission comprising the steps of:
 a) identifying said individual; and,   b) administering to said individual an antibody which specifically binds to p185.   
     
     
         13 . The method of  claim 12  wherein the antibody has the complementarity determining regions from an antibody selected from the group consisting of 7.16.4 and 7.9.5. 
     
     
         14 . The method of  claim 12  wherein the antibody has the variable region from an antibody selected from the group consisting of 7.16.4 and 7.9.5. 
     
     
         15 . The method of  claim 12  wherein the antibody is selected from the group consisting of 7.16.4 and 7.9.5. 
     
     
         16 . The method of  claim 12  wherein the antibody is 7.16.4. 
     
     
         17 . The method of  claim 12  wherein the antibody is a humanised antibody with complementarity determining regions selected from an antibody the group consisting of 7.16.4 and 7.9.5. 
     
     
         18 . The method of  claim 12  wherein the antibody is a humanised antibody with complementarity determining regions from antibody 7.16.4. 
     
     
         19 . The method of  claim 12  wherein the antibody is a humanised antibody with variable regions selected from an antibody the group consisting of 7.16.4 and 7.9.5. 
     
     
         20 . The method of  claim 12  wherein the antibody is a humanized antibody with variable regions from antibody 7.16.4. 
     
     
         21 . The method of  claim 12  further comprising administering to said individual a second antibody which specifically binds to p185. 
     
     
         22 . The method of  claim 12  further comprising administering to said individual an anti-tumor agent.

Join the waitlist — get patent alerts

Track US2011274688A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.